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populated with relevant cost, adherence and epidemiological data for Belgium from a 
health care perspective and the results were presented in cost (c2009) per quality-
adjusted life-year (QALY) gained. Analyses were performed in populations (over 60 
years) where osteoporosis medications are currently reimbursed in many European 
countries, i.e. bone mineral density T-score is below or equal to −2.5 or presence of 
prevalent vertebral fracture. Univariate and probabilistic sensitivity analyses were 
conducted to assess the robustness of the results. RESULTS: The cost-effectiveness of 
denosumab compared with generic alendronate was estimated at c38,875, c20,690 
and c26,153 per QALY for women with T-score ≤−2.5 aged 60, 70 and 80 years, 
respectively. The equivalent values were c37,856, c18,764 and c17,309 per QALY 
for women with prevalent vertebral fractures. Discount rates, fracture risk and 
patient’s adherence to generic alendronate were found to be particularly sensitive when 
varied within the model. At 70 years of age, probabilistic sensitivity analyses showed 
that the probability of the ICERs remaining below c40,000 is 84% in women with 
prevalent vertebral fracture and 74% in those with T-score ≤−2.5, conﬁ rming the 
cost-effectiveness of denosumab. CONCLUSIONS: This study suggests that deno-
sumab is a cost-effective strategy (cost per QALY gained ≤c40,000) compared with 
generic alendronate for the treatment of postmenopausal Belgian osteoporotic women, 
aged 60 years and above.
PMS41
THE IMPACT OF MEDICATION ADHERENCE ON THE COST OF 
OSTEOPOROSIS FRACTURES IN GERMANY: A MODELLING APPROACH
Stephens JM1, Brotherton SA1, Gitlin MD2, Steinle T3, Leidl R4, Kochevar JJ1
1Kochevar Research Associates, Charlestown, MA, USA; 2Amgen (Europe) GmbH, Zug, 
Switzerland; 3Amgen (Europe) GmbH, München, Germany; 4Ludwig Maximilian University, 
Munich, Germany
OBJECTIVES: Current osteoporosis therapies can reduce the risk of fractures and 
thus costs, but adherence to these medications is often poor. We estimated yearly 
potential savings in fracture-related costs from improved adherence to osteoporosis 
therapies in Germany from a societal perspective. METHODS: The model was a 
deterministic cohort model estimating annual treatments and outcomes for German 
women aged ≥50 years old in 2010 (n = 17,689,849), by f5 year cohorts. Demographic 
parameters were drawn from government databases, medication prescription share 
from industry databases, fracture incidence (hip, clinical vertebral, and non-hip, non 
vertebral (NHNV)), medication adherence (medication possession ratio MPR, one 
year intervals) and efﬁ cacy from published literature. As a base case we estimated 
4.2% treated (n = 745,313) with oral bisphosphonates (94.6%), strontium (2.7%) 
and raloxifene (2.6%); 54% with effective adherence (MPR > 50%). Fracture related 
costs (excluding medication costs) included direct medical, long-term nursing care, 
and work loss. The model parameters are adjustable, allowing real time calculation 
of outcomes. We estimated current costs with 54% effectively adherent and 100% 
effectively adherent. RESULTS: The model calculated total fracture-related costs for 
all patients in 2010 at c4.4 billion (with 69.6% for direct medical costs, 20.2% for 
long-term nursing care, and 10.2% for work loss). For the estimated 4.2% of treated 
patients, the model calculated total fracture-related costs at c184.9 million. Increasing 
the percentage of patients with effective adherence from 54% to 100% decreased costs 
for hip (16.2%), vertebral (24.4%) and NHNV fractures (6.3%). CONCLUSIONS: 
Adjustable parameters allow users to calculate yearly fracture-related costs and savings 
for different economic perspectives and decision options. According to one run using 
the above parameters, achieving full adherence to medication among women currently 
treated for osteoporosis in Germany would reduce fractures, and cut down annual 
fracture related costs by c27.8 million (15.1%).
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OBJECTIVES: To evaluate the cost-effectiveness of certolizumab pegol (CZP) either 
as an add-on therapy to methotrexate (MTX) or as monotherapy versus other biologi-
cal DMARDs, in the treatment of patients with active RA who did not respond 
adequately to DMARDs, including MTX, in the United Kingdom (UK). METHODS: 
A cost-utility model with a Markov structure was developed following BSR and NICE 
guidelines. Comparators considered in the analysis were licensed and recommended 
TNF-α inhibitors in England and Wales (etanercept [ETA], adalimumab [ADA] and 
inﬂ iximab [IFX]), + MTX or as monotherapy (ETA and ADA only). Clinical efﬁ cacy, 
history and resource use data came from published literature. Unit costs were taken 
from routine sources/published references. Utilities were derived from EQ-5D data 
collected in CZP RA clinical trials. Cost for CZP assumed the ﬁ rst 12 weeks free of 
charge, as per the patient access scheme. Base-case analysis was conducted from the 
NHS perspective, with lifetime horizon, costs and outcomes discounting rates of 3.5%. 
Sensitivity analyses were conducted. RESULTS: Base-case analysis indicated that CZP 
is cost-effective compared with all combination and monotherapies considered. 
CZP+MTX dominated the comparators considered. CZP+MTX was associated with an 
incremental gain in quality-adjusted life-years (QALYs) of 0.242, 0.065 and 0.458 when 
compared with ADA+MTX, ETA+MTX and IFX+MTX, respectively. Total costs for 
CZP+MTX were lower than comparator combination therapies by £451, £582 and 
£10,016, respectively. CZP+MTX had the highest probability of being cost-effective of 
the TNF inhibitor + MTX therapies considered (at £20,000/QALY, 53.6% for 
CZP+MTX, 25% for ETA+MTX, 21.2% for ADA+MTX, 0.2% for IFX+MTX). 
Among monotherapies, CZP dominated ADA (QALY incremental gain: 0.215, total 
costs lower by £2,352 vs. ADA). CZP was cost-effective below a willing-to-pay threshold 
of £31,582/QALYs vs. ETA. CONCLUSIONS: This analysis indicates that CZP is a 
cost-effective treatment for RA in the UK.
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OBJECTIVES: To assess the cost-utility and multinomial expected value of perfect 
information (mEVPI) of sequenced treatment with biologics in moderate-to-severe 
rheumatoid arthritis (msRA) after failure of traditional disease modifying antirheu-
matic drug(s) (tDMARD). METHODS: A probabilistic, individual sampling (micro-
simulation) model was developed to compare ten different treatment sequences 
among 3,000 hypothetical Finnish msRA patients in a lifetime scenario. 
Adalimumab+methotrexate (MTX), etanercept+MTX or tocilizumab+MTX were 
used as ﬁ rst biologics followed by up to three other biologics. Best supportive care 
including tDMARDs was assumed to be used after exhaustion of treatment options 
with biologics. Treatment with MTX alone was added as further comparator. The 
clinical outcomes (no ACR50, ACR50 and ACR70 responses conditional to the use 
of biologic drugs) were obtained from a recently published mixed treatment compari-
son and quality-adjusted life-years (QALY) were estimated based on disease severity 
scores (HAQ) using a nonlinear equation: EQ5D = 0.82-0.11*HAQ-0.07*HAQ2. 
Resource use was estimated from published references and valued with Finnish unit 
costs (year 2009). Analyses were performed from payer perspective (productivity losses 
were excluded) using 3% annual discount rate. RESULTS: Compared to MTX alone, 
treatment with tocilizumab+MTX was more cost-effective than treatment with 
etanercept+MTX. Both tocilizumab+MTX and etanercept+MTX dominated 
adalimumab+MTX. An additional QALY gained with tocilizumab+MTX costs 
c15,478 (mEVPI c1,258/patient) compared with MTX alone. An additional QALY 
gained with tocilizumab+MTX followed by etanercept+MTX costs c35,543 (mEVPI 
c748/patient) compared with tocilizumab+MTX. According to cost-effectiveness 
acceptability frontier, only MTX alone, tocilizumab+MTX or tocilizumab+MTX fol-
lowed by etanercept+MTX should be considered, if willingness to pay is c0–50,000 
per QALY gained. With c30,000 per QALY gained, tocilizumab+MTX had 97.6% 
probability of being cost-effective. The results were relatively robust in sensitivity 
analyses. CONCLUSIONS: After tDMARD failure, tocilizumab+MTX or 
tocilizumab+MTX followed by etanercept+MTX were the most cost-effective biolog-
ics for patients with msRA. mEVPI indicated that the value of additional research 
information is low.
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OBJECTIVES: To measure the impact of obesity on annual medical and productivity 
costs among working U.S. adults with arthritis. METHODS: We conducted a cross 
sectional study using Medical Expenditure Panel Survey data from 2003–2007. 
Working adults with arthritis (18–64 years old) were selected if they did not have 
pregnancy, malignancy, kidney dialysis, immunodeﬁ ciency, low body mass index (BMI 
< 18.5 kg/m2), or unemployed status. Patients with arthritis were identiﬁ ed by ICD-9 
codes of 714–715 or via patient self-report. Obese and normal- weight were deﬁ ned 
as BMI of ≥30 kg/m2 or BMI of 18.5–<25 kg/m2, respectively. Loss of productivity 
was estimated by loss of workdays due to illness or injury and standard hourly wage 
by occupation. Medical costs were estimated using a generalized linear model with a 
log link function and gamma distribution. Costs of productivity loss were calculated 
using a two-part model to adjust for patients with zero costs. Using Oaxaca decom-
position, differences in treatment costs between obese and normal-weight patients 
were decomposed into two parts: a) differences in characteristics (endowments) across 
groups, and b) differences between obese and normal parameters (coefﬁ cients). Costs 
attributable to obesity were deﬁ ned as the costs by coefﬁ cients component. All costs 
were converted to 2009 U.S. dollars using price indices. RESULTS: Among the 7345 
working adults with arthritis, prevalence of obesity and normal-weight was 24.8% 
vs. 40.7%, respectively. The difference in medical costs between the groups was 
US$2380 (95% CI: US$1934–2825) due to endowments and US$379 (95% CI: 
US$367–392) due to coefﬁ cient components. Productivity loss costs in the obese 
patients were higher, at US$46(95% CI: US$ 41–51) due to endowments and 
US$441(95%CI: US$435–447) due to coefﬁ cient components. CONCLUSIONS: Use 
of the Oaxaca decomposition method suggested that the economic burden, particu-
larly productivity loss costs, of obesity in patients with arthritis was substantial, 
adjusting for characteristics across groups.
